| 周剂量多西他赛单药或联合奈达铂二线治疗晚期非小细胞肺癌效果比较 |
| |
| 引用本文： | 甄振华,申传厚,陶雄飞,李婉萍,赵敏敏. 周剂量多西他赛单药或联合奈达铂二线治疗晚期非小细胞肺癌效果比较[J]. 肿瘤研究与临床, 2014, 0(2): 87-90 |
| |
| 作者姓名： | 甄振华 申传厚 陶雄飞 李婉萍 赵敏敏 |
| |
| 作者单位： | 安徽省淮北市人民医院肿瘤科,235000 |
| |
| 摘 要： | 目的 比较周剂量多西他赛（DOC）单药或联合奈达铂（NDP）二线治疗晚期非小细胞肺癌（NSCLC）的疗效、不良反应及预后。方法 回顾性分析接受二线化疗的晚期NSCLC 56例，其中单药组34例接受DOC治疗（35 mg／m2，第1、8天），联合组22例接受DOC联合NDP治疗（DOC 35 mg／m2，第1、8天，NDP 80 mg／m2，第2天），均21 d为1个周期，2个周期后评价疗效和不良反应。结果 单药组和联合组有效率（RR）分别为8.8 %（3／34）和27.3 %（6／22），疾病控制率（DCR）分别为50.0 %（17／34）和63.6 %（14／22），中位无进展生存期（PFS）分别为2.3个月和5.1个月，中位总生存期（OS）分别为8.7个月和10.5个月，1年生存率分别为26.5 %和31.8 %，差异均无统计学意义（均P＞0.05）。联合组Ⅲ～Ⅳ度白细胞下降为7例，单药组为2例，差异有统计学意义（χ2＝4.877，P＝0.027），其他不良反应如消化道反应、乏力等多为Ⅰ～Ⅱ度。结论 周剂量单药DOC二线治疗晚期NSCLC安全、有效，毒性较低，但与周剂量DOC联合NDP相比较，有效率和生存期无优势。
|
| 关 键 词： | 癌，非小细胞肺 多西他赛 奈达铂 二线化疗 |
Efficacy comparison on treating advanced non-small-cell lung cancer between using weekly docetaxel and using docetaxel associated with nedaplatin |
| |
| Zhen Zhenhua,Shen Chuanhou,Tao Xiongfei,Li Wanping,Zhao Minmin. Efficacy comparison on treating advanced non-small-cell lung cancer between using weekly docetaxel and using docetaxel associated with nedaplatin[J]. Cancer Research and Clinic, 2014, 0(2): 87-90 |
| |
| Authors: | Zhen Zhenhua Shen Chuanhou Tao Xiongfei Li Wanping Zhao Minmin |
| |
| Affiliation: | . (Department of Oncology, the People ＇s Hospital of Huaibei City, Huaibei 235000, China) |
| |
| Abstract: | Objective To compare the efficacy, toxicity and prognosis on treating advanced non-small-cell lung cancer （NSCLC） between using weekly docetaxel （DOC） and using DOC associated with nedaplatin（NDP）. Methods 56 cases of NSCLC patients were retrospectively analyzed. Group A included 34 cases who were treated with weekly DOC （35 mg/m2, d1,8）. Group B included 22 cases who were treated with DOC associated with NDP （DOC 35 mg/m2, d1,8, NDP 80 mg/m2, d2）. One treatment cycle was 21 days. Efficacy, toxicity and prognosis were evaluated after 2 treatment cycles. Results RR of group A was 8.8 % （3/34）. RR of group B was 27.3 % （6/22）. DCR of group A was 50.0 % （17/34）. DCR of group B was 63.6 % （14/22）. PFS of group A was 2.3 months. PFS of group B was 5.1 months. OS of group A was 8.7 months. OS of group B was 10.5 months. 1-year survival rate of group A was 26.5 %. 1-year survival rate of group B was 31.8 %. The above comparisons were not statistically different （all P 〉 0.05）. In adverse reactions, hematologic toxicity in group B was greater than that in group A （χ 2 = 4.877, P = 0.027）. Other adverse reactions such as gastrointestinal reactions, fatigue and so on were grade Ⅰ-Ⅱ. Conclusions The treatment of weekly DOC used in advanced NSCLC is safe, effective an low toxicity. There are no significant difference of RR and PFS between single DOC and DOC associated with NDP. |
| |
| Keywords: | Carcinoma non-small-cell lung Docetaxel Nedaplatin Second-line chemotherapy |
| 本文献已被 维普 等数据库收录！ |
|
